text:
WASHINGTON -- Over the past four years, the Democrats blamed the Republicans for ushering in "a culture of corruption" that they charged had infected every nook and cranny of the government.
The lobbying payoffs and influence-peddling scandals did indeed bring down a number of Republicans, though it turned out that many Democratic lawmakers also had received tainted contributions from the same lobbyists or their clients. But that got less attention from the national news media.
Now the tide has turned against the Democrats on two fronts, and it is they who are being investigated on corruption charges just as they were poised to take over the White House and strengthen their legislative grip on Congress.
Rod Blagojevich's pay-to-play scandal, in which he has plotted to sell Barack Obama's Senate seat to the highest bidder, has pushed the Illinois governor to the brink of impeachment. But it has also embarrassed and distracted the president-elect and his transition advisers, and a top election analyst says the GOP could end up winning the vacated seat.
Obama is not implicated in the scandal, but many questions were raised about whether his designated chief of staff, Rep. Rahm Emanuel -- a hard-hitting practitioner of Chicago-style politics -- is the "president-elect adviser" mentioned in the U.S. Attorney's complaint that details Blagojevich's plans to put Obama's seat up for sale.
Meanwhile, Rep. Charles Rangel of New York, the powerful chairman of the tax-writing House Ways and Means Committee, is being investigated for, among other things, failure to pay his taxes and helping a rich donor to obtain a tax loophole in return for a large contribution to a public-service center named in Rangel's honor.
Last week, Republicans were attacking Democrats with a vengeance for being corrupt -- unleashing a barrage of press releases promoting a flood of newspaper stories about their latest troubles with headlines that read, "Democrats web of corruption continues to grow," "Rangel's troubles create a problem for the Democrats" and "Did Obama team have contact with Illinois governor?"
The smell of a scandal "might be building, though it's not there yet," said Jennifer Duffy, senior political analyst at the Cook Political Report. "But Democrats who have won on this message of culture of corruption now find the tables have turned on them, and they do have to be very careful that it doesn't get bigger," Duffy told me.
For Barack Obama, "it's a distraction he doesn't need right now," she said.
Scandal-wise, this has been a bumper year for the Democrats, who have seen some of their biggest names brought down by one investigation after another.
Donald Lambro is chief political correspondent for The Washington Times.
I Was A Woman In The Marine Corps In the Mid-70s. Hillary Clinton's Story Doesn't Add Up | Susan Hutchison
Ted Cruz to Marco Rubio: Stop impugning my patriotism by claiming I'm soft on national security | Allahpundit

subset: commoncrawl


text:
Nikki Reed on how her own maternal instincts came out after filming scenes with Renesmee:
"Elizabeth Reaser will tell you that I'm very maternal because I cooked for her. I love children. I do. I don't want any right now. I'm not ready. But I love being around them. Mackenzie, by the way, is like the most professional. I know it seems like sort of an obvious thing to say because we should say that about her, but I'm constantly impressed with her ability to sort of cope with everything and how normal she is and how normal her mother is. My apartment was across the hall from them, and I think that was sort of done on purpose so we could bond and spend time together. I was alone, single and alone, while we were filming, so I would spend almost every night cooking with her and her family. I think it totally changed the tone of the set. There was a child around, so we all had to behave ourselves."
© 2015 Whalerock Industries


text:
Exhibit uses everyday objects to explore the concept of time
11:13 PM, Nov. 30, 2013
Most Viewed
Email this article
Exhibit uses everyday objects to explore the concept of time
Prepare to be mesmerized by the Diane Landry exhibition at the Contemporary Arts Center: The five kinetic sculptures and two videos on view are captivating, but it takes a little time to let their
A link to this page will be included in your message.
Buy & Sell
Use our mobile site and iPhone apps to keep updated with what's going on around Cincinnati.
View the last seven days
- Yesterday, Nov 28
- Friday, Nov 27
- Thursday, Nov 26
- Wednesday, Nov 25
- Tuesday, Nov 24
- Monday, Nov 23
- Sunday, Nov 22
See our paid archives for news older than a week.
Real Deals
Flip, shop and save on specials from your favorite retailers in the Tri-State area.GET DEALS NOW


text:
DIY: Installing steering wheel audio and phone controls on Camaro !
Well gm is finally listening. when i get mine in ill let you know what pins and terminal end numbers
#PIC5320: Adding Radio Steering Wheel Control Switch (RPO NZL) - (Jan 26, 2010)
Subject:Adding Radio Steering Wheel Control Switch (RPO NZL)
Models:2010 Chevrolet Camaro
The following diagnosis might be helpful if the vehicle exhibits the symptom(s) described in this PI.
Condition/Concern:
A customer may inquire if it is possible to install steering wheel mounted audio controls on a vehicle that was not originally built with that option.
Recommendation/Instructions:
It is possible to install audio Steering Wheel Controls (SWC) at the customer's expense. This modification will require installation of the appropriate right hand steering wheel control switch, Steering Wheel Pad Accessory harness, and recalibration of the BCM. You may need to contact Techline Customer Support Center (TCSC) for a VCI number to recalibrate the BCM. Since this is not a warrantable repair, TCSC may charge a fee for this service.
Please follow this diagnostic or repair process thoroughly and complete each step. If the condition exhibited is resolved without completing every step, the remaining steps do not need to be performed.
GM bulletins are intended for use by professional technicians, NOT a "do-it-yourselfer". They are written to inform these technicians of conditions that may occur on some vehicles, or to provide information that could assist in the proper service of a vehicle. Properly trained technicians have the equipment, tools, safety instructions, and know-how to do a job properly and safely. If a condition is described, DO NOT assume that the bulletin applies to your vehicle, or that your vehicle will have that condition. See your GM dealer for information on whether your vehicle may benefit from the information.
APPROXIMATE price of parts:
switch: 92219336 $25.45
harness (auto w/paddle shift): 92236307 $31.10
harness (manual): 92236309 $38.92
http://gsi.xw.gm.com/image_en_us/gif.../999999994.gif WE SUPPORT VOLUNTARY TECHNICIAN CERTIFICATION
Just give me a few more days to get my parts and check wiring that way you can install and wire. That way all you pay for is the programming. Trust me the actual switch and harness is not hard. to run wire to the bcm isnt either but they will charge you like it is the most difficult thing in the world because they dont know what to do. If nothing else i will post bcm connector and pin number also steering wheel end that way you can hand it to them and they dont have to charge you for looking it up and "diagnosis" of how to install.
I am now the proud owner of a 1ss w/ steering wheel controls. all buttons work including mute and volume and even phone for onstar. Bring in document i posted earlier pic5320. doc id# 2388518 with you to service dept. I talked to techline assistance w josh he was very helpful you might let the tech know to talk to him so you can get it programmed. $50 programming fee from techline plus what dealer will charge to program and install harness if you chose to go that route. will post pics with instructions on how to install to trey and save you some money after i get home and off work. Thanks for all the patience and good luck. any questions feel free to message me and ask. WE HAVE VICTORY PEOPLE
Yes either order complete wheel or parts listed earlier for auto or stick. It works great.:thumbup::thumbup::thumbup::thumbup:
2 Attachment(s)
sorry guys had some technical problems with my home computer had to charge laptop. anyways here goes as requested part numbers are as follows switch 92219336 harness for six speed manual 92236309 harness for auto w paddle shift 92236307.
7 Attachment(s)
first step as always is to disconnect the battery so as to not set off the airbags. dont be afraid of them if you are careful they are not a problem with no power. there is a small hole in the side of the steering wheel insert a small tool i use a flat blade pocket screw driver and push in on the metal tabs i took pics of the tabs w air bag off to show you what you are pushing against
3 Attachment(s)
next remove the air bag connectors using that same screw driver carefully pry under the retainer to remove then pry up on connector and it will come lose same for both connectors
3 Attachment(s)
next disconnect the wires by pressing in on one wire connectors and releasing retainer one going to steering wheel coil
5 Attachment(s)
next cut green tie strap or whatever color is there holding harness to wheel new harness comes with new retainers. then the fun part removing the silver trim ring around wheel basically it is just pressed into the rubber in the wheel. carefully pry it loos around the edges and it will come out
10 Attachment(s)
next remove the blank filler on right side of wheel and install new switch. next unplug harness from left switch and discard. install new harness to switches and press the silver trim ring back into wheel startin at inside of switches and moving out
5 Attachment(s)
then install new wires onto retainer making sure not to pinch any wires black on left green on right. then reinstall the air bag connectors pushing them in first then pushing in retainers fully finally just line up airbag and push it onto wheel firmly. reconnect battery and get your bcm programmed at dealer. side note the switch light will work right away but not the features themselves until you get it updated
well guys sorry about the big pics had to load off of flash drive from work couldnt resize. I hope this helps and saves you some money and problems at the dealer. would love to hear if you are as successful as i am and if you have any questions ill check back tomorrow and every once in a while. like i said before $50 program fee they will charge from techline plus what they charge to install update in your bcm. again the guy at techline i talked to is josh and he said he would try and help and said i could give out his name to help in easier programming and less wait time. probably about an hour total to get program from gm and install in car. if they wont do it or say it cant be done let me know and ill do it at our dealer in alabama. far for some of you but hopefully you wont need it with all this info. thanks again for the support and thank you toasty for the document you found couldnt have gotten it taken care of without that..:clap::clap::clap:
this is excellent dude !!!! great job !!!!!!!!
so how much are all the parts then plus the service charges? would just be nice to have the total cost all in one post. thanks so much for your diligence and work in getting this done for the community
The labor will depend on the hourly rate of your dealer. The dealer I go to charges $92/hour.
techsupport, you ARE the man!!!!!!!!!!
Im sorry to say i dont have the answer for that one. i actually work at a gm dealer so i got the parts at cost and all i had to pay for was the 50 dollar techline fee since i work in service dept i didnt have to pay for install and program fee. normally we charge half an hour for programming so whatever the labor rate is in your area plus the parts and $50 fee for special program again sorry but i dont know how much it will cost total
if you want i can get with the parts guy and see what the switch and harness would cost normally together but i dont know on the labor. just dont let them get you on the fee for vci program it is only $50 from gm and then what they charge to install in your car
if you wouldn't mind getting the pricing from the parts guy on the switch and the harness that would rock... I can do the install itself so really just have to worry about paying for the parts and the reprogram. Thanks very much techsupport. People like you is why this community kicks ass.
Thanks for all the info TechSupport, I think I'm gonna change the wheel myself, do you know what size Torx drive I will need to remove my steering wheel bolt? The Manual tells me what the Torgue spec is, but not the size.
Edit: I found out the size of the Torx Drive is T45. Changed it myself, now to get it activated.
Well I answered my own question... gmpartsdirect.com breaks it down like this
switch: 92219336 $25.45
harness (auto w/paddle shift): 92236307 $31.10
harness (manual): 92236309 $38.92
It would be interesting to see what the parts guy at the dealership would want for them to see the markup. I was at my dealership yesterday and my sales guy, Patrick, called over and checked for me to see how much some splash guards would be and the lowest, with Patrick's employee discount was $170. They're $145 on gmpartsdirect. There's always some markup. I can't imagine it being too bad on the switch and the harness but, who knows. Capitalism at it's finest.
Great news Techsupport, YOU ARE THE MAN!!!!!!!!!! I think I will be doing this mod very soon myself.
I'd like to ask a question concerning any impacts to the warranty. Does this affect our warranty in anyway?
I ask this because I was advised by my local dealer that changes to the BCM programming can/will void the warranty "in total" because it modifys the build sheet.
I'm not trying to start a debate or dampen this great acheivement. I'm just wanting to know what, if any, impacts this may cause. If we are charged the fee for reprogramming, does this mean that it is supported under the warranty??
Techsupport, can you look into this for us and advise on how GM support views this mod??? Please..
Just dropped about $400 at gmpartsdirect. Ordered the PDIM, splash guards, and the steering wheel switch and harness. Now here's to hoping the dealership won't assrape me on updating the radio and BCM. I figure getting it all done at once would be the smart move. Now, on to today's projects. Installing a CAI and stripping the wax off and Zainoing it. I'll post back in this thread once I get everything installed and software updated. I bet gmpartsdirect is going to have an influx of orders now that techsupport has gotten this to work. Way to go buddy.
as far as warranty goes the dealerships usually say it will block warranty for one of two reasons. one they have no idea to do what you are asking and two an aftermarket program will change warranty. Here is the beautiful thing about this the parts and program are gm. they cant say you messed up the bcm by installing their program. when the techline programs your car they write a new program to your vin. if and when you had a bcm go bad and got it replaced at any gm dealer when they went to replace and reprogram there wouldnt be an issue because it would reprogram for steering wheel controls without them doing anything it will already be part of your cars program from now on. with the bulletin i posted gm is admitting to letting you install this program. the reason warranty will not cover it and you have to pay for the program is because it is basically an accessory like a set of running boards on a truck or adding heated seat package supported by gm. you still have to pay for them and the install because there is nothing wrong with your vehicle. warranty issues are only covered if there is a defect or something wrong with your vehicle. the only thing wrong is that gm didnt offer this in the 1ss to begin with. hope that clears it up for you.
damn thata awesome
Badass! Bookmarking this one, as she really wants the cloth seats, but I can't live without the gauge cluster and the sw audio controls- makes the steering wheel look balanced. Great write up! Thanks for posting!
|All times are GMT -5. The time now is 02:40 PM.
Powered by vBulletin® Version 3.8.9 Beta 4
Copyright ©2000 - 2015, vBulletin Solutions, Inc.


text:
Paid Vacation – June, 2012
The theme of our June, 2012 Story Slam was Paid Vacation. Check out the stories told this night!
Peter Cunniffe won the "Paid Vacation" Story Slam with this story of his business trip to Puerto Rico and how the payoff dwindled over time.
Shayna Parker tells about taking a working trip to New Orleans – and how she hopes to return one day on her own.
Richard Fritzson tells about how confusion over train seats in Italy led to some very tense moments with an elderly Italian couple. The result, once he had it translated was quite startling.
Stephanie Ostroff tells about her trip to Prague, and her trip back to Italy was disrupted due to volcanic ash and her changed travel plans proved quite rewarding.
Italian men can be a bit touchy and invade women's private space. Celeste Montgomery tells about what happened in an Italian square with her friends (who were nuns) and how one Italian man went too far.
Mikey Gleason tells the story of a recent trip to Italy, where he learned something new about earthquakes.
Joanne Rafferty tells about a vacation where she went horseback riding and had a misunderstanding with the local ranch hands.
http://www.youtube.com/watch?v=2jyd_4f2daQRetired schoolteacher Rick Stevenson gives a few reasons why teachers deserve a "Paid Vacation" each summer.
Mark Schneider tells stories about his Paid Vacation, when he worked in NYC for four years.


text:
Decreased expression of inwardly rectifying potassium (Kir) channels in astrocytes and glioma cells may contribute to impaired K+ buffering and increased propensity for seizures. Here, we evaluated the potential effect of inflammatory molecules, such as interleukin-1β (IL-1β) on Kir4.1 mRNA and protein expression.
We investigated Kir4.1 (Kcnj10) and IL-1β mRNA expression in the temporal cortex in a rat model of temporal lobe epilepsy 24 h and 1 week after induction of status epilepticus (SE), using real-time PCR and western blot analysis. The U373 glioblastoma cell line and human fetal astrocytes were used to study the regulation of Kir4.1 expression in response to pro-inflammatory cytokines. Expression of Kir4.1 protein was also evaluated by means of immunohistochemistry in surgical specimens of patients with astrocytic tumors (n = 64), comparing the expression in tumor patients with (n = 38) and without epilepsy (n = 26).
Twenty-four hours after onset of SE, Kir4.1 mRNA and protein were significantly down-regulated in temporal cortex of epileptic rats. This decrease in expression was followed by a return to control level at 1 week after SE. The transient downregulation of Kir4.1 corresponded to the time of prominent upregulation of IL-1β mRNA. Expression of Kir4.1 mRNA and protein in glial cells in culture was downregulated after exposure to IL-1β. Evaluation of Kir4.1 in tumor specimens showed a significantly lower Kir4.1 expression in the specimens of patients with epilepsy compared to patients without epilepsy. This paralleled the increased presence of activated microglial cells, as well as the increased expression of IL-1β and the cytoplasmic translocation of high mobility group box 1 (HMGB1).
Taken together, these findings indicate that alterations in expression of Kir4.1 occurring in epilepsy-associated lesions are possibly influenced by the local inflammatory environment and in particular by the inflammatory cytokine IL-1β.
Keywords:Epilepsy; Inflammation; Potassium channels; Interleukin-1 β; Astrocytes; Brain tumors
Astrocytes, the major glial cell type of the central nervous system (CNS), are known to play a major role in normal brain signaling and their dysfunction has been shown to be critically involved in the pathogenesis of several human CNS disorders, including epilepsy (for reviews see [1,2]). One of the most important physiological functions of astrocytes is their ability to control ionic homeostasis, in particular the extracellular concentration of potassium, which influences neuronal excitability. The inwardly rectifying potassium (Kir) channel 4.1 has been identified as a key player among the potassium channels expressed in astrocytes responsible for spatial buffering [3,4]. Conditional knock-out of Kir4.1 has been shown to lead to inhibition of potassium and glutamate uptake, hyperexcitability, and seizures [5,6]. Mutations in the human Kir4.1 gene, KCNJ10, are associated with epilepsy [7] and a compromised glial potassium spatial buffering has been suggested to underlie the epilepsy phenotype [8]. In addition, alterations in expression, localization, and function of Kir4.1, have been reported in astrocytes in a number of neurological disorders, including temporal lobe epilepsy (TLE) and malignant gliomas (for review see [9]). In tissue specimens obtained from patients with epilepsy, both electrophysiological and molecular studies suggest that impaired potassium buffering and enhanced seizure susceptibility may result from reduced expression of Kir4.1 channels [10-14]. In the fluid percussion injury model in rat, a chronic dysfunction of Kir channels (with depletion of Kir4.1 immunoreactivity in processes of neocortical astrocytes) in the epileptic focus has been reported [15]. In case of astrocytic tumors, which are often associated with seizure development, mislocalization, and/or redistribution of Kir4.1, as well as changes in the expression related to the malignancy grade, have been reported [9,16-18]. In addition, attention has been focused on the role of Kir channels as critical regulators of cell division, suggesting that a loss of functional Kir4.1 may underlie the re-entry of glial cells into the cell cycle supporting gliosis and tumor development [9]. Although these observations support an important role for astrocytic Kir4.1, it remains still unclear whether the changes in Kir4.1 expression represent the cause or the consequence of epilepsy and the mechanism underlying the regulation of the expression of Kir4.1 is still matter of discussion. It has been shown that albumin uptake into astrocytes, mediated by transforming growth factor (TGF)-β receptors, produces a downregulation of Kir4.1 in these cells [19]. In spinal cord injury, the downregulation of Kir4.1 has been suggested to be dependent on the nuclear estrogen receptor signaling [20]. Moreover, recently, Kir4.1 expression has been suggested to be influenced by changes in the extracellular environment of inflammatory cytokines, such as interleukin-1β (IL-1β) [21]. Interestingly, increasing evidence supports the notion that dysregulation of the astrocyte immune-inflammatory function is a common factor predisposing or directly contributing to the generation of seizures in epilepsy of various etiologies [1,22,23].
Our major aim was to investigate the potential effect of inflammatory molecules, such as IL-1β on Kir4.1 expression using both a glioblastoma cell line and human astrocytes in culture.
The anti-inflammatory effects of the antiepileptic drug (AED) levetiracetam reported recently in vivo and in vitro[24,25], prompted us to evaluate the effect of this AED on Kir4.1 expression in cultures exposed to IL-1β. In addition, in order to detect changes in Kir4.1 expression and/or localization in tumor astrocytes and their relationship to IL-1β expression and to the tumor epileptogenicity, astrocytic tumors with and without epilepsy were studied.
Materials and methods
Experimental animals
Adult male Sprague–Dawley rats (Harlan CPB laboratories, Zeist, The Netherlands) weighing 300 to 500 g were used in this study which was approved by the University Animal Welfare committee. The rats were housed individually in a controlled environment (21 ± 1°C; humidity 60%; lights on 08:00 to 20:00; food and water available ad libitum).
Electrode implantation and seizure induction
In order to record hippocampal EEG, a pair of insulated stainless steel electrodes (70 μm wire diameter, tips were 80 μm apart) were implanted into the left dentate gyrus (DG) under electrophysiological control as previously described [26]. A pair of stimulation electrodes was implanted in the angular bundle. Rats underwent tetanic stimulation (50 Hz) of the hippocampus in the form of a succession of trains of pulses every 13 s. Each train had a duration of 10 s and consisted of biphasic pulses (pulse duration 0.5 ms, maximal intensity 500 μA). Stimulation was stopped when the rats displayed sustained forelimb clonus and salivation for minutes, which usually occurred within 1 h. However, stimulation never lasted longer than 90 min. Differential EEG signals were amplified (10×) via a FET transistor that connected the headset to a differential amplifier (20×; CyberAmp, Axon Instruments, Burlingame, CA, USA), filtered (1 to 60 Hz), and digitized by a computer. A seizure detection program (Harmonie, Stellate Systems, Montreal, Canada) sampled the incoming signal at a frequency of 200 Hz per channel. EEG recordings were monitored also visually and screened for seizure activity. Behavior was observed during electrical stimulation and several hours thereafter. Immediately after termination of the stimulation, periodic epileptiform discharges PEDs) occurred at a frequency of 1 to 2 Hz and they were accompanied by behavioral and EEG seizures (status epilepticus).
Rat tissue preparation for RNA isolation and western blot analysis
After decapitation, the brain was removed and dissected and the temporal cortex was cut out of the slices under a dissection microscope. Rats were decapitated in the acute phase (1 day after SE, n = 6) and in the latent period (1 week after SE, n = 6; the rats in this group did not exhibit spontaneous seizures). Age-matched rats that were implanted but not stimulated except for field potential recordings were also included (n = 6). All material was frozen on dry ice and stored at −80°C until use. For western blot analysis frozen samples of control (n = 5), 1 day post SE (n = 5), and 1 week after SE (n = 5) were homogenized in lysis buffer (as described below) and protein content was determined using the bicinchoninic acid method [27].
Cell cultures
For experiments with astrocytes-enriched human cultures, fetal brain tissue (15 to 23 weeks of gestation) was obtained from spontaneous or medically-induced abortions with appropriate maternal written consent for brain autopsy. Resected tissue samples were collected in Dulbecco's modified Eagle's medium (DMEM)/HAM F10 (1:1) medium (Gibco, Life Technologies), supplemented with 50 units/mL penicillin and 50 μg/mL streptomycin and 10% fetal calf serum (FCS). Cell isolation was performed as previously described [28,29]. Briefly, after removal of meninges and blood vessels, tissue was minced and dissociated by incubation at 37°C for 20 min in a Hank's balanced salt solution containing 2.5 mg/mL trypsin (Sigma, St. Louis, MO, USA) and 0.1 mg/mL bovine pancreatic Dnase I (Boehringer Mannheim, Germany). Tissue was triturated and washed with DMEM/HAM F10 medium, supplemented with 50 units/mL penicillin and 50 μg/mL streptomycin and 10% FCS. Cell suspension (containing approximately 0.5 g wet weight tissue/10 mL culture medium) was passed through a 70 μm cell sieve (Becton Dickinson, USA) and plated into 25 cm2 flasks (Falcon, Lincoln Park, NJ, USA) and maintained in a 5% CO2 incubator at 37°C. After 48 h the culture medium was replaced by fresh medium and cultures were subsequently fed twice a week. Cultures reached confluence after 2 to 3 weeks. Secondary astrocyte cultures were established by trypsinizing confluent cultures and sub-plating into 6- and 24-well plates (Costar; 0.5 × 106 cell/well in a 6-well plate for western blot analysis or 0.1 × 106 cell/well in a 24-well plate for RNA isolation and PCR) and simultaneously into 12 mm coverslips (Sigma) in 24-well plates (Costar; 2 × 104 cell/well; for immunocytochemistry). More than 98% of the cells in primary culture, as well as in the successive 12 passages, were strongly immunoreactive for the astrocytic marker GFAP and S100β. In the present study astrocytes were used for immunocytochemical analyses at passage 3 to 4. The astrocytoma cell line U373 was obtained from the American Type Culture Collection (Rockville, MD, USA); cells were cultured in DMEM/HAM F10 (1:1) supplemented with 50 units/mL penicillin, 50 μg /mL streptomycin and 10% FCS.
Treatment of cell cultures
Human recombinant (r)IL-1β (Peprotech, NJ, USA; 10 ng/mL) was applied and maintained for 24 h before harvesting the cells for RNA isolation, western blot analysis or for immunocytochemistry. In some experiments different time periods of IL-1β exposure (ranging from 10 min to 48 h) were used and rIL-6 (10 ng/mL; Strathmann Biotec A.G., Hamburg, Germany), tumor necrosis factor α (TNFα; 1 ng/mL; Peprotech, NJ, USA) and high mobility group box 1 (HMGB1; 40nM; HMGBiotech S.r.l., Milan, Italy) alone or together with IL-1β were applied and maintained in the medium for 24 h before harvesting the cells for RNA isolation. Human IL-1receptor antagonist (IL-1Ra; 1 μg/mL; Peprotech, NJ, USA) was used to neutralize IL-1β activity (applied 1 h before IL-1β). As previously shown [29] the viability of human astrocytes in culture was not influenced by the treatments. In other experiments, cells exposed to IL-1β (for 24 h) were extensively washed with phosphate-buffered saline (PBS) and incubated up to 48 h in culture medium, before harvesting them for western blot analysis.
Preparation of cellular extracts
Cells were harvested at 24 h after treatment and washed twice with cold PBS. The samples were homogenized in lysis buffer containing 10 mM Tris (pH 8.0), 150 mM NaCl, 10% glycerol, 1% NP-40, Na orthovanadate (10.4 mg/mL), 5 mM EDTA (pH 8.0), 5 mM NaF and protease inhibitor cocktail (Boehringer Mannheim, Germany) by incubating on ice for 15 min. The homogenates were centrifuged at 14,000 rpm for 10 min and the supernatant was used for further analysis.
Western blot analysis
Western blot analysis was performed, as previously described [30]. For electrophoresis, equal amounts of proteins (15 to 20 μg/lane) were separated on a 10% sodium dodecylsulfate-polyacrylamide gel electrophoretic (SDS-PAGE) gel. Separated proteins were transferred to nitrocellulose paper for 90 min at 100 V, using a wet electroblotting system (BioRad, Hercules, CA, USA). Membranes were blocked for 1 h in 5% non-fat dry milk in Tris-buffered saline-Tween (TBST) (20 mM Tris, 150 mM NaCl, 0.1% Tween 20, pH 7.5). The blots were incubated overnight with the primary antibody (Kir4.1 rabbit polyclonal antibody 1:1,000 in 5% milk solution, Alomone Labs, Jerusalem, Israel).
After several washes in TBST, the membranes were incubated in TBST/5% non-fat dry milk, containing the goat anti-rabbit or rabbit anti-mouse coupled to horse radish peroxidase (1:2,500; Dako, Denmark) for 1 h. After washes in TBST, immunoreactivity was visualized using ECL PLUS western blotting detection reagent (GE Healthcare Europe, Diegen, Belgium). Expression of β-actin (monoclonal mouse, Sigma, St. Louis, MO, 1:50,000) or β-tubulin (monoclonal mouse, Sigma, St Louis, MO, 1:30,000) were used as loading control. For the quantification of the blots the band intensities were measured densitometrically using the Scion Image for Windows (beta 4.02) image-analysis software. A ratio of the band intensity of the protein of interest to that of the reference protein was used to normalize expression.
RNA isolation and real-time quantitative PCR analysis (qPCR)
For RNA isolation, 800 μL Trizol LS Reagent (Invitrogen, Carlsbad, CA, USA) was added to 0.1 to 0.5 × 106 cells. After addition of 200 μg glycogen and 200 μL chloroform, the aqueous phase was isolated using Phase Lock tubes (5 Prime GmBH, Hamburg, Germany). RNA was precipitated with isopropyl alcohol, washed with 75% ethanol and dissolved in water. The concentration and purity of RNA were determined at 260/280 nm using a nanodrop spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA).
Five micrograms of total RNA were reverse-transcribed into cDNA using oligo dT primers. Five nmol oligo dT primers were annealed to 5 μg total RNA in a total volume of 25 μL, by incubation at 72°C for 10 min, and cooled to 4°C. Reverse transcription was performed by the addition of 25 μL RT-mix, containing: First Strand Buffer (Invitrogen-Life Technologies), 2 mM dNTPs (Pharmacia, Germany), 30 U RNAse inhibitor (Roche Applied Science, Indianapolis, IN, USA) and 400 U M-MLV reverse transcriptase (Invitrogen - Life Technologies, The Netherlands). The total reaction mix (50 μL) was incubated at 37°C for 60 min, heated to 95°C for 10 min and stored at −20°C until use.
PCR primers (Eurogentec, Belgium) were designed using the Universal Probe Library of Roche (https://www.roche-applied-science.com webcite) on the basis of the reported mRNA sequences. For the rat we used: Kir4.1/Kcnj10 (forward: gtgacaggcaaactgcttca and reverse: gggctatcagaggctgtgtc); IL-1β (forward: aaaaatgcctcgtgctgtct; reverse: tcgttgcttgtctctccttg); and GAPDH (forward: atgactctacccacggcaag; reverse: tactcagcaccagcatcacc). For the human cell cultures we used: Kir4.1 (forward: acctcggacccaagatgac; reverse: gtatccctgggcccattag); IL-1β (forward: gcatccagctacgaatctcc reverse: gaaccagcatcttcctcagc); elongation factor 1-alpha (EF1α; forward: atccacctttgggtcgcttt; reverse: ccgcaactgtctgtctcatatcac); and hypoxanthine phosphoribosyl transferase (HPRT; forward: tggcgtcgtcgtgattagtgatg; reverse: tgtaatccagcaggtcagca). For each PCR, a mastermix was prepared on ice, containing per sample: 1 μL cDNA, 2.5 μL of FastStart Reaction Mix SYBR Green I (Roche Applied Science, Indianapolis, IN, USA), 0.4 μM of both reverse and forward primers. The final volume was adjusted to 5 μL with H2O (PCR grade). The LightCycler® 480 Real-Time PCR System (Roche-applied-science) was used with a 384-multiwell plate format. The cycling conditions were carried out as follows: initial denaturation at 95°C for 5 min, followed by 45 cycles of denaturation at 95°C for 15 s, annealing at 55 to 60°C for 5 s and extension at 72°C for 10 s. The fluorescent product was measured by a single acquisition mode at 72°C after each cycle. For distinguishing specific from non-specific products and primer dimers, a melting curve was obtained after amplification by holding the temperature at 65°C for 15 s followed by a gradual increase in temperature to 95°C at a rate of 2.5°C s-1, with the signal acquisition mode set to continuous. Quantification of data was performed using the computer program LinReg PCR in which linear regression on the Log(fluorescence) per cycle number data is applied to determine the amplification efficiency per sample [31]. The starting concentration of each specific product was divided by the starting concentration of reference genes (GAPDH, for rat material; HPRT and EF1a for the cell cultures) and this ratio was compared between patient/control groups.
Human material
The human cases included in this study were obtained from the files of the departments of neuropathology of the Academic Medical Center (AMC, University of Amsterdam) and the VU University Medical Center (VUMC), both situated in Amsterdam and both tertiary referral centers for brain tumor patients in the Netherlands. We examined immunocytochemically 73 surgical specimens of brain tumor patients with astrocytic tumors (6 WHO grade II astrocytoma; 12 WHO grade III astrocytoma; 55 glioblastoma multiforme, GBM; Table 1). Normal-appearing control cortex/white matter was obtained at autopsy from eight adult control patients without a history of seizures or other neurological diseases. All autopsies were performed within 12 h after death. Cortical samples (cortex/white matter adjacent to the lesion with reactive changes, such as astrogliosis, but not tumor cells) of five patients with non-glial brain tumors (two meningiomas, one metastasis of carcinoma, and one lymphoma) and without refractory epilepsy were also analyzed (control cortex/surgical, Table 1). Frozen tissue from histologically normal cortex (n = 2) and GBM (n = 4) samples was used for western blot analysis and total RNA prepared from normal cortex (n = 6) and GBM (n = 8; four with epilepsy and four without epilepsy) was used for qPCR.
Table 1. Clinical and histopathological features
A chart review was conducted of all patients. Epilepsy was defined as the experience of one or more seizures and data regarding seizure frequency and seizure type were obtained from patient histories. We collected additional data including age, gender, tumor location, and epilepsy duration. Informed consent was obtained for the use of brain tissue and for access to medical records for research purposes. Tissue was obtained and used in a manner compliant with the Declaration of Helsinki. Two neuropathologists reviewed all cases independently and the diagnosis was confirmed according to the revised WHO classification of tumors of the central nervous system [32].
Tissue preparation for immunocytochemistry
Tissue was fixed in 10% buffered formalin and embedded in paraffin. Paraffin-embedded tissue was sectioned at 5 μm, mounted on precoated glass slides (Star Frost, Waldemar Knittel GmbH, Brunschweig, Germany) and used for immunohistochemical staining as described below.
Antibodies specific for glial fibrillary acidic protein (GFAP; polyclonal rabbit, DAKO, Glostrup, Denmark; 1:4,000; monoclonal mouse; DAKO; 1:50), vimentin (mouse clone V9; DAKO; 1:1,000), neuronal nuclear protein (NeuN; mouse clone MAB377; Chemicon, Temecula, CA, USA; 1:2,000), synaptophysin (mouse clone Sy38; DAKO; 1:200; rabbit anti-synaptophysin; DAKO; 1:200), Ki67 (mouse clone MIB-1; DAKO; 1:200), (HLA)-DP, DQ, DR (HLA-DR; mouse clone CR3/43; DAKO, Glostrup, Denmark, 1:400), MAP2 (mouse clone HM2; Sigma 1:100) and p53 (Clone DO-7 + BP53-12; Neomarkers; 1:2,000), were used in the routine immunohistochemical analysis of glial tumors. For the detection of Kir4.1, we used a polyclonal rabbit antibody (Alomone Labs, Ltd, Jerusalem, Israel; 1:100); for the detection of IL-1β a polyclonal goat antibody (sc-1250, Santa Cruz Bio., CA, USA; 1:70; [33]) and for the detection of HMGB, we used a polyclonal rabbit antibody (Pharmingen, San Diego, CA, USA; 1:100; [34]; Abcam Cambridge, UK).
Paraffin-embedded sections were deparaffinized, re-hydrated, and incubated for 20 min in 0.3% H2O2 diluted in methanol to quench the endogenous peroxidase activity. Antigen retrieval was performed by incubation for 10 min at 121°C in citrate buffer (0.01 M, pH 6.0), sections were washed with phosphate-buffered saline (PBS) and incubated for 30 min in 10% normal goat serum (Harlan Sera-Lab, Loughborough, Leicestershire, UK).
Coverslips with adherent cells (U373 or fetal astrocytes) were rinsed in PBS (pH 7.4) and fixed for 15 min in 4% paraformaldehyde in PBS. After rinsing, cultures were incubated in PBS containing 10% normal goat serum for 15 min prior to the incubation with the primary antibodies.
Sections were incubated with the primary antibodies overnight at 4°C. Hereafter, sections were washed in PBS and the ready-for-use Powervision peroxidase system (Immunologic, Duiven, The Netherlands) and 3,3'-diaminobenzidine (DAB; Sigma) was used to develop the color reaction. Sections were counterstained with hematoxylin, dehydrated and coverslipped. Sections incubated without the primary antibody were essentially blank. To test the specificity of the antibody, western blot analysis of the total homogenates of human histologically normal cortex (n = 2) and GBM (n = 4) samples was performed, as described above. The number of available frozen tumor samples from patient with and without epilepsy was too small to perform meaningful statistical comparisons in subgroups and to assess whether Kir4.1 expression is more directly dependent on presence or absence of seizures or tumor type by western blot analysis.
Evaluation of immunostaining
Semi-quantitative evaluation of immunoreactivity (IR) in tumor specimens was performed as previously [33,35] using a using a semi-quantitative scale ranging from 0 to 3 (0: -, no; 1: +/−, weak; 2: +, moderate; 3: ++, strong IR). Two representative sections per case were stained and assessed with the Kir4.1 and IL-1β antibodies. The intensity score represents the predominant staining intensity found in each specimen as averaged from the selected fields and the different sections per group. The evaluation of the IR in tumor specimens was performed in the center of the lesion, the infiltration zone was disregarded. The sections were evaluated by two independent observers blind to clinical data. In case of disagreement independent reevaluation was performed by both observers to define the final score. The approximate proportion of cells showing IR (0, <1%; 1, single to 25%; 2, 26% to 50%; 3, 51% to 75%; and 4, >75%) was also scored to give information about the relative number ('frequency' score) of positive cells tumor specimens. As proposed before [36,37], the product of these two values (intensity and frequency scores) was taken to give the overall score (immunoreactivity total score; IR score), shown in Tables 2 and 3. We also evaluated the IR score of HLA-DR (markers of microglia activation) in tumor tissue of patients with or without epilepsy and quantitative analysis was performed for HMGB1 in these two patient groups, as previously described [34]. Briefly, three representative adjacent non-overlapping fields of the areas of interest (A II, A III, and GBM) were captured (magnification 40×) and digitized (Leica DM5000B). We counted the total number of astroglial/tumor cells and those showing nuclear or extra-nuclear HMGB1 staining.
Table 2. Kir4.1 and IL-1β immunoreactivity in astrocytic tumors
Table 3. Kir4.1 and IL-1β immunoreactivity in patients with/without epilepsy and with/without levetiracetam use
In cell cultures (U373 and fetal astrocytes) quantitative analysis was carried out for the number of Kir4.1 immunoreactive cells. All cells were counted systematically at high magnification (×40 objective; using an ocular grid and counting 1,000 cells from two separate experiments) as positive IR (including strong or intermediate intensity of labeling) or negative. The percentage of labeled Kir4.1 was calculated based on the total number of cells.
Statistical analysis
Statistical analysis was performed with SPSS 15.0 and Prism® (Graph Pad Software, Inc.) software for Windows. To assess differences between groups, a non-parametric Kruskal-Wallis test was performed, followed by the Mann–Whitney U test. Correlations between Kir4.1 immunostaining and different variables (histopathological diagnosis, epilepsy, the use of levetiracetam and IL-1β immunoreactivity) were assessed with the Mann–Whitney U test and the Spearman's rank correlation test. The value of P <0.05 was defined as statistically significant. Multiple testing was corrected by the Bonferroni correction.
Kir4.1 and IL-1β expression in rat temporal cortex after induction of SE
To determine the temporal-spatial expression of Kir4.1 expression we performed qPCR in tissue samples of control rats and rats that were sacrificed at different time points after SE (1 day and 1 week post SE). Kir4.1 expression significantly decreased at 24 h post SE and returned toward control levels at 1 week after the onset of SE (Figure 1A). Western blot analysis of total homogenates of rat temporal cortex revealed a band at molecular weight of approximately 40 kDa which showed a significant decrease at 24 h post SE as compare to controls (Figure 1C, D). The transient prominent decrease of Kir4.1 mRNA expression following SE prompted us to evaluate whether this decrease might be related to an increased level of cytokines, such as IL-1β. Prominent IL-1β upregulation was indeed observed 24 h post SE (Figure 1B).
Figure 1. Kir4.1 and IL-1β expression in rat temporal cortex after status epilepticus (SE). (A, B) Quantitative real-time PCR. mRNA expression levels of Kir4.1 (A) and IL-1β (B) in the temporal cortex of control rats (n = 6; Con), rats at 1 week (n = 6), and 3 months (n = 6) after SE. Data represent the target gene expression normalized to the reference genes. The error bars represent SEM and * represents a P value <0.05. (C, D) Western blot analysis of Kir4.1. (C) Representative immunoblot of total homogenates from temporal cortex of controls and post SE (24 h and 1 week) rats. (D) Densitometric analysis: values (optical density units, O.D.) are mean ± SEM, (control, n = 5; 24 h post SE, n = 5; and 1 week post SE, n = 5), relative to the optical density of β-tubulin; *P <0.05, compared to controls.
Regulation of Kir4.1 expression by IL-1β in human glial cells in culture
To address the question of whether IL-1β was involved in the modulation of Kir4.1 expression we used both human fetal astrocytes and the U373 glioblastoma cell line in culture. qPCR demonstrated that exposure to IL-1 β consistently decreased Kir4.1 expression in both cell types (Figure 2A and B). The effect of IL-1β was blocked by the IL-1Ra, a naturally occurring antagonist of the IL-1β receptor ([38]; Figure 2C). IL-1β significantly decreased Kir4.1 mRNA levels already 30 min after exposure to IL-1β (not shown) and its effect was maximal at 24 h. The downregulation of Kir4.1 mRNA could be partially reverted when IL-1β was removed and cultures were incubated for 48 h in culture medium (Kir4.1 expression (relative to control of 100%): 24 h IL-1β: 13.8% ± 2.0; 48 h after washout: 51.3% ± 2.7). In contrast, under our culture conditions we did not observe significant changes in the expression levels of Kir4.1 after exposure to IL-6 (10 ng/mL), TNFα (1 ng/mL), or HMGB1 (40nM); cytokine treatments, including IL-1β, did not influence the expression of Kir2.1, 2.3, and 3.1 mRNA (not shown).
Figure 2. Kir4.1 expression in U373 glioblastoma cell line and in cultured human astrocytes after exposure to IL-1β. (A-C) Quantitative real-time PCR. Expression levels of Kir4.1 mRNA 24 h after exposure to IL-1β (10 ng/mL) in U373 glioblastoma cell line (A) and in cultured human astrocytes (B). (C) Expression levels of Kir4.1mRNA 24 h after exposure to IL-1β in U373 cell line in the presence or absence of the IL-1 β receptor antagonist (IL-1Ra; 1 μg/mL) or levetiracetam (LEV; 10 μg/mL). Data are expressed relative to the levels observed in unstimulated cells (untreated controls, Con) and are mean ± SEM from two separate experiments performed in triplicate (*P <0.05; ***P <0.0001 compared to control). (D, E). Western blot analysis of Kir4.1. Representative immunoblot of total homogenates from U373 glioblastoma cell line (D) and from human fetal astrocytes (E) untreated and treated for 24 h with 10 ng/mL IL-1β, in the presence or absence of the IL-1 β receptor antagonist (IL-1Ra; 1 μg/mL). Densitometric analysis: values (optical density units, O.D.) are mean ± SEM, relative to the optical density of β-actin; *P <0.05, compared to controls.
The recently described anti-inflammatory property of the AED levetiracetam [24,25] prompted us to evaluate its effect on IL-1β–induced Kir4.1 downregulation. Exposure to levetiracetam did not affect IL-1β induced Kir4.1 downregulation. However levetiracetam treatment (for 24 h) significantly increased Kir4.1 mRNA compared to untreated cells (Figure 2C). A similar effect was observed 48 h after exposure to levetiracetam (not shown).
Western blot analysis confirmed the downregulation of Kir4.1 induced by IL-1β in U373 cells (Figure 2D) and fetal astrocytes (Figure 2E) at the protein level. No significant differences (at 24 h) in Kir4.1 protein levels were detected in either cell culture after treatment with levetiracetam (in the presence or absence of IL-1β; not shown).
In both astrocytes-enriched human cell cultures and glioma cells incubated with IL-1β, immunocytochemistry demonstrated a lower percentage of Kir4.1-labeled cells as compared to controls (Figure 3A-F). In U373 cells (but not in fetal astrocytes), we also observed nuclear IR (Figure 3A and B) in addition to cytoplasmic Kir4.1 IR.
Figure 3. Kir4.1 (IR) in U373 glioblastoma cell line and in cultured human astrocytes after exposure to IL-1β. (A-D) representative photomicrographs showing Kir4.1 IR in glioma cells (U373; A, B) and cultured human astrocytes (C, D), untreated (A and C; Con) and treated (B and D) for 24 h with 10 ng/mL IL-1β; high magnifications are shown in the inserts; in U373 cells Kir4.1 was also detected in the nuclei of glial cells (insert in A and B). Scale bar in A: A and B: 80 μm; C and D: 40 μm. (E and F): percentage of Kir4.1 positivity in glioma cells (U373; E) and cultured human astrocytes (F) untreated and treated for 24 h with 10 ng/mL IL-1β. *P <0.05, compared to untreated controls (Con).
Kir4.1 and IL-1β expression in human astrocytic tumors
Table 1 summarizes the clinical and histopathological characteristics of the patients and control cases. Thirty-eight of the seventy-three tumor patients had epilepsy. The majority of the patients had secondary generalized seizures, followed by simple partial seizures. All 42 patients with epilepsy used antiepileptic drugs, 14 of them used levetiracetam before operation.
Kir4.1 immunoreactivity
In control tissue we did not detect obvious differences in the distribution of Kir4.1 between surgical and autopsy cortical specimens. Kir4.1 IR was detected around blood vessels (Figure 4A) as previously reported [16,17] and occasionally in the cytoplasm of astroglial cells. Astrocytoma WHO grade II and III, as well as GBM displayed mainly cytoplasmic staining in tumor cells (Figures 4B-F). The expression at perivascular endfeet membranes was less prominent and occasionally nuclear expression was observed in astrocytoma grade III and GBM (not shown). The IR score was significantly lower in astrocytoma grade II compared to control cortex, as well as astrocytoma grade III (Table 2). GBM showed variable Kir4.1 expression and the IR score was not significantly different compared to the other tumor subtypes (Table 2; Figure 4E and F). The variable Kir4.1 expression in GBM is also reflected by western blot analysis of total homogenates (Figure 4G). However, in this retrospective study, the number of frozen specimens available was too small to perform statistical comparisons in subgroups.
Figure 4. Expression of Kir4.1 immunoreactivity (IR) in glial tumor from patients with and without epilepsy. (A) Control white matter showing Kir4.1 IR in processes of perivascular astrocytes. (B) Astrocytoma grade II (A II); (C-F) Representative photomicrographs of Kir4.1 IR in astrocytoma grade III (A III; C and D) and glioblastoma multiforme (GBM; E and F) with (C and E) and without epilepsy (D and F); inserts: high magnifications, showing cytoplasmic staining, with weak IR in epilepsy-associated tumors. Sections were counterstained with hematoxylin. Scale bars: A: 40 μm; B-F: 160 μm. (F) Representative immunoblot of total homogenates from control cortex and GBM (with and without epilepsy) that revealed a band at a molecular weight of approximately 40 kDa.
Figure 5. Expression of IL-1β immunoreactivity (IR) in glial tumors from patients with and without epilepsy. Representative photomicrographs of IL-1β IR in control white matter (A) astrocytoma grade II (A II; B, with epilepsy), astrocytoma grade III (A III; A-D) and glioblastoma multiforme (GBM; E and F) with (C and E) and without epilepsy (D and F); inserts: high magnifications, showing strong IR in epilepsy-associated tumors. Sections were counterstained with hematoxylin. A-F: scale bar in A: 80 μm.
Figure 6. Kir4.1 and IL-1β mRNA expression in glioblastoma multiforme (GBM) from patients with and without epilepsy. Quantitative real-time PCR. Expression levels of Kir4.1 (A) and IL-1β (B) mRNA in GBM from patients with (n = 4) and without epilepsy (n = 4). Data are expressed relative to the levels observed in control cortex (n = 5) and are mean ± SEM (*P <0.05; compared to control and GBM without epilepsy).
Figure 7. HLA-DR and HMGB1 expression in glial tumors from patients with and without epilepsy. (A-D) Representative photomicrographs of HLA-DR IR in astrocytoma grade III (A III; A and B) and glioblastoma multiforme (GBM; C and D) with (A and C) and without (B and D) epilepsy, showing immmunoreactive cells in epilepsy associated tumors. (E-H) Representative photomicrographs of HMGB1 IR in A III (E and F) and GBM (G and H) with (E and G) and without (F and H) epilepsy, showing cytoplasmic staining (arrows in E and G) in epilepsy-associated tumors. Sections were counterstained with hematoxylin. Scale bars: A-C: 160 μm; E-H: 60 μm. (I) Quantification bargrams of HMGB1-positive cells in tumors with and without epilepsy. Extranuclear staining in epilepsy associated tumors: *P <0.05 vs. tumors without epilepsy.
Figure 8. Expression of Kir4.1 and IL-1β immunoreactivity (IR) in glial tumors from patients with epilepsy, with and without levetiracetam use. Representative photomicrographs of Kir4.1 (A and B; high magnifications in inserts) and IL-1β (C and D) IR in glioblastoma multiforme (GBM) without (A and C) and with (B and D) levetiracetam treatment (LEV); Sections were counterstained with hematoxylin. A-D: scale bar in D: 80 μm.
Kir4.1 expression and epilepsy
The expression and distribution of Kir4.1 IR was compared in tumor tissue of patients with astrocytoma WHO grade II, WHO grade III and GBM with or without epilepsy. A significantly lower Kir 4.1 expression was found in tumor tissue of patients with epilepsy (Figure 4B, C, E; Table 3). qPCR demonstrated lower Kir 4.1 mRNA expression in GBM with epilepsy compared to GBM without epilepsy (Figure 6A).
The number of astrocytomas grade II and grade III with and without epilepsy was too small to perform a meaningful statistical comparison between these subgroups so that we could not assess whether Kir 4.1 expression is dependent on the presence of seizures or tumor type.
IL-1β immunoreactivity
As previously reported [33], IL-1β was under detection level in both surgical and autopsy cortical specimens of healthy controls (Figure 5A). Expression of IL-1β was detected in the different tumor subtypes in tumor cells (Figure 5B to F). The IR score for each tumor and control tissue is summarized in Table 2. The IR score was significantly higher in astrocytoma grade II, III, as well as GBM compared to control cortex. No significant differences were detected between tumor subtypes (Table 2). Astrocytoma grade II, III, as well as GBM displayed also higher IR score for HLA-DR compared to controls (Table 2).
IL-1β expression and epilepsy
A significantly higher IL-1β expression was observed in tumor tissue of patients with epilepsy (Figure 5B, C, E; Table 3). qPCR demonstrated higher IL-1β mRNA expression in GBM with epilepsy compared to GBM without epilepsy (Figure 6B). Tumor tissue of patients with epilepsy displayed also a higher IR score for HLA-DR compared to controls (Table 3; Figure 7A-D). We also evaluated the cellular localization of HMGB1, a nuclear protein that can also act as an extracellular signal of inflammation [39-41]. We observed increased cytoplasmic translocation of HMGB1 IR in tumor tissue of patients with epilepsy compared to patients without epilepsy (Figure 7E-I).
The number of astrocytomas grade II and grade III with and without epilepsy was too small to perform a meaningful statistical comparison in these subgroups. The Spearman's rank correlation test was applied to evaluate the relationship between Kir4.1 and IL-1β IR. A weak but significant negative correlation was observed between the Kir4.1 and the IL-1β IR score (r = −0.3663; P <0.05). No significant correlations were found between Kir4.1 or IL-1β IR and clinical variables such as age at surgery, age at seizure onset, and duration of epilepsy.
Kir4.1 expression in levetiracetam-treated patients
The expression of Kir4.1 was evaluated in relation to AED regimens, in particular to levetiracetam treatment in patients with epilepsy. A significantly higher Kir4.1 IR was observed in the patients treated with levetiracetam compared to the patients who were not treated with this AED (Table 3; Figure 8A-B). In contrast a lower expression of IL-1β (Table 3; Figure 8C-D) was observed in levetiracetam-treated patients, whereas no differences were observed for HLA-DR. In addition, the seizure free interval was evaluated in levetiracetam-treated patients to assess whether Kir4.1 expression was associated with the presence of seizures and whether it was influenced by levetiracetam treatment. Of the 14 patients with epilepsy who were treated with levetiracetam, six patients were seizure free, six patients were not, and in one patient no data regarding seizure free interval was available. Kir4.1 expression was not correlated with seizure free interval in levetiracetam-treated patients.
The present study investigated the effect of the proinflammatory molecule IL-1β on the expression of Kir4.1, a major K+- inward rectifying channel in astrocytes. In addition, the expression pattern of Kir4.1 in primary human glial tumors and its relationship to seizure activity and inflammation was studied. The following observations were made: (1) in a rat model of TLE, Kir4.1 mRNA and protein were significantly downregulated in temporal cortex 24 h after onset of SE; this downregulation corresponded to the time of prominent upregulation of IL-1β; (2) IL-1β treatment reduced the expression of Kir4.1 mRNA and protein in both a glioma cell line and human astrocytes in culture; (3) Kir4.1 expression was lower in tumors with epilepsy compared to tumors without epilepsy; (4) astrocytic tumors with epilepsy displayed higher IL-1β IR compared to tumors without epilepsy; (5) among the patients with epilepsy, a significantly higher Kir4.1 IR was detected in the patients treated with levetiracetam compared to the patients who did not use this antiepileptic drug. The significance of these findings in relation to epileptogenesis in astrocytic tumors is discussed below.
Downregulation of Kir4.1 mRNA after induction of SE parallels the increased IL-1β expression
Impaired potassium buffering and enhanced seizure susceptibility have been suggested to result from reduced expression of Kir4.1 channel in TLE ([10-14]; for review see [2]). A previous micro-array study in the electrical post-SE rat model showed that several potassium channel genes, including Kir channels were found to be downregulated 24 h after induction of SE in the CA3 region of the hippocampus [42]. The present study confirmed the downregulation of Kir4.1 mRNA at 24 h post SE in the temporal cortex. However, this decrease in expression (both mRNA and protein) recovered to control levels after the latent period. A recent study suggests a role for inflammatory cytokines, such as IL-1β, in the regulation of the expression of Kir4.1 [21]. Interestingly, experimentally-induced seizures in rodents trigger a rapid upregulation of IL-1β and its receptor ([42,43]; for review see [1,22]). IL-1β is among the best-characterized early-response inflammatory cytokines and a key mediator in the response of the brain to various forms of CNS injury (for review see [44-46]. Accordingly, in the present study, it was observed that IL-1β peaked in the temporal cortex at 1 day after SE, which corresponds to the time point of prominent reduction of Kir4.1 expression. A decrease of functional Kir channels has been shown in other pathologies associated with activation of the inflammatory response, including amyotrophic lateral sclerosis and retinopathies ([47-49]; for review see [9]). These observations suggest a role for IL-1β in the regulation of Kir4.1 mRNA expression, which was further investigated in vitro, using glial cells in culture.
IL-1β treatment downregulated Kir4.1 expression human glial cells
Both U373 glioblastoma cells and human fetal astrocytes in culture expressed Kir4.1 mRNA and protein. Immunocytochemical analysis showed cytoplasmic expression of Kir4.1 in human astrocytes, whereas both cytoplasmic and nuclear expression was observed in glioma cells. This is in agreement with previous studies reporting a mislocalization of Kir channels to the nucleus in glioma cell lines [18]. In the present study, IL-1β treatment significantly decreased Kir4.1 mRNA levels in both the U373 glioma cell line and fetal astrocytes in culture. This effect (already observed at 30 min and maximal at 24 h after exposure to IL-1β) could explain the suppression of Kir4.1 mRNA expression observed after seizure-induced release of this cytokine in vivo. Under our experimental conditions, the effect of downregulation of Kir4.1 expression observed with IL1-β treatment could not be reproduced by other pro-inflammatory cytokines, such as IL-6 and TNFα or the toll-like receptor 4 agonist, HMGB1. The observation that IL-1Ra inhibited the effect of IL-1β on suppression of Kir4.1 is consistent with the fact that IL-1β signals through the type I IL-1β receptor. IL-1Ra is a naturally occurring antagonist of the IL-1 receptor [38], which is also regulated in response to different forms of CNS insult (for review see [1,22,50]). Thus, it is tempting to speculate that differential expression of inhibitory components of the IL-1 system and in particular local changes in the IL-1Ra/IL-1β ratio in brain, may critically contribute to the regulation of Kir4.1 expression under both physiological and pathological conditions. Moreover, the effect of IL-1β was partially reversible, with Kir4.1 levels showing partial recovery 48 h after removal of the cytokine. These observations suggest that the expression of Kir4.1 mRNA could be critically influenced by local dynamic changes in the level of IL-1β in the extracellular environment.
Recently, anti-inflammatory effects have been reported for levetiracetam [24,25], an AED frequently used to treat partial onset seizures, also in patients with brain tumors ([35,51]). In particular, treatment with this AED in neonatal rat astrocytes that were co-cultured with activated microglia or treated with IL-1β has been shown to restore impaired astrocyte membrane resting potentials via modification of inward and outward rectifier currents [25]. These studies prompted us to evaluate the effect of levetiracetam on IL-1β–induced Kir4.1 downregulation observed in human astrocytes and glioma cells. Under our experimental condition, levetiracetam was not able to counteract the downregulatory effect of IL-1β on Kir4.1 mRNA. It could be conceived that this lack of effect of levetiracetam on IL-1β treated cells is related to the dose of the cytokine used. Further experiments using different IL-1β doses in combination with levetiracetam are ongoing to address this issue. However, in the absence of IL-1β, levetiracetam positively regulated Kir4.1 mRNA expression. The potential effect of a chronic exposure to levetiracetam on IL-1β and Kir4.1 protein expression was further investigated in surgical astrocytic tumor specimens from patients treated with levetiracetam.
Differential expression of Kir4.1 and IL-1β in astrocytic tumors
Immunocytochemical analysis showed variable Kir4.1 expression in astrocytic tumors with mainly cytoplasmic staining in tumor cells. Decrease of IR in glial processes and particularly in perivascular astrocyte endfeet was observed in both low- and high-grade gliomas, whereas nuclear expression was detected only occasionally in high-grade gliomas. Thus, the localization in the nucleus observed in glioma cell lines in culture ([18]; present study) does not represent a consistent feature of human primary glial tumor. Accordingly, nuclear localization has not been reported in other studies analyzing the expression pattern of Kir4.1 in surgical specimens of both low- and high-grade astrocytomas [16,17]. However, in agreement with our observations, Warth and colleagues [16] reported a redistribution of Kir4.1 in astrocytomas (with reduced perivascular astrocyte endfeet), suggesting a compromised buffering capacity of glial tumor cells. In our study the IR score was significantly lower in astrocytoma grade II compared to astrocytomas grade III, whereas no differences were observed compared to GBM. Tan and colleagues [17] investigated the expression of Kir4.1 mRNA and protein in astrocytic tumors and reported higher expression in high-grade astrocytic tumors compared to low-grade tumors. They suggested that activation of Kir4.1 produced intracellular alkalinization and could promote proliferation and inhibit apoptosis in the tumors [17]. In contrast, other studies suggest that the function of Kir4.1 channel is correlated with an exit from the cell cycle (for review see [9]). Thus the consequences of alterations in Kir4.1 expression on the proliferation of astrocytic tumors are still unclear and remain to be further explored. Moreover, in these previous studies [16,17], no information concerning the presence/absence of epilepsy or about the AED treatment in epileptic patients was available and considered in the evaluation of the correlation between Kir4.1 expression and pathologic tumor grade.
In the present study, we evaluated the expression of Kir4.1 and IL-1β in patients in relation to the presence or absence of epilepsy. We found a significantly lower Kir4.1 expression in tumor tissue of patients with epilepsy, which paralleled the increased expression of IL-1β. The IL-1β-mediated downregulation of Kir4.1 expression could represent an additional mechanism contributing to the pro-epileptogenic effect of this cytokine. In our study we found a significant higher IL-1β expression in tumor tissue of patients with epilepsy and a significant (although weak) negative correlation with the expression levels of Kir4.1. Interestingly, a recent study shows that minocycline treatment in the retina of diabetic rats, increases Kir4.1 levels and this effect is associated with a decrease of the levels of IL-1β [21].
Cytokine production, including also IL-1β, has been previously reported in human astrocytoma cell lines and surgical specimens of astrocytic tumors ([52-55] for review see [56]). We confirmed IL-1β expression in tumor cells, of both low- and high-grade astrocytomas, in agreement with the notion that astroglial cells represent a main source of brain IL-1β [1,57]. Accordingly, high expression of IL-1β has also been reported in tumor astrocytes in ganglioglioma, which represent a well-known cause of chronic intractable epilepsy [33]. The expression of IL-1β in tumor astrocytes may be involved in enhancing neuronal excitability in the peritumoral region (for reviews see [1,57]). A cytokine-mediated inhibition of glutamate reuptake by astrocytes may lead to increased extracellular glutamate concentrations [58,59]. Additionally, IL-1β has been shown to increase nitric oxide production and cortical glutamate release [60]. Furthermore, IL-1β may also regulate gamma-aminobutyric acid (GABA)-mediated Cl- fluxes (possibly reducing inhibitory transmission) and molecular and functional interactions between IL-1β and N-methyl-D-asparte (NMDA) receptors have been recently reported (for reviews see [1,57]). Substantial experimental evidence supports the proconvulsant role of IL-1β (for review see [1,57,61]). Thus, production of IL-1β by tumor astrocyes may (through different mechanisms) contribute to the epileptogenicity of glial tumors (for review see [51]). Interestingly, the higher expression of IL-1β in tumors associated with epilepsy was linked with increased presence of activated microglial cells, as well as with the cytoplasmic translocation of HMGB1, which may contribute to amplify the inflammatory response via a signaling pathway involving the TLR4 [34]. Relocation of the nuclear protein to the cytoplasm has been shown to be induced in rat [62] and human cultured astrocytes and glioma cells by IL-1β [63]. In addition, a potential role for HMGB1 has been suggested in promoting growth and migration of human glioblastoma cells [64].
Since rapid changes in IL-1β and Kir4.1 expression are induced by seizures in experimental models (present results; for review see [1,57,61]), we cannot exclude that seizure activity may contribute to their level of expression. No significant correlation was found between Kir4.1 (or IL-1β) IR and duration of epilepsy in our cohort. However since our study does not focus on long-term epilepsy-associated tumors (LEATs; [65]), future investigations on a large cohort of LEATs are necessary to address the relationship between Kir4.1 expression and /or function and duration and/or severity of epilepsy.
As discussed above, anti-inflammatory effects have been reported for levetiracetam [24,25]. In particular, treatment with this AED (but not with valproic acid) has been shown to reduce reactive gliosis and expression levels of IL-1β in the hippocampus and the piriform cortex in chronic epileptic rats [24]. These observations prompted us to evaluate the expression levels of both IL-1β and Kir4.1 in relation to AED treatment, in particular the exposure to levetiracetam. Among the patients with epilepsy who were treated with levetiracetam, we found significantly higher expression levels of Kir4.1, and, conversely, lower expression of IL-1β, compared to patients who did not use this AED. These observations, together with previous experimental findings [24] suggest that an anti-inflammatory effect (targeting the IL-1β system) could, at least in part, contribute to the anti-epileptic effect of levetiracetam.
We acknowledge limitations to the interpretation of these results, since the cohort was relatively small to assess whether Kir4.1 expression is directly dependent on the presence or absence of seizures or on tumor type. Further quantitative analysis and in vitro electrophysiological studies are needed to confirm these findings and to establish their functional significance. However, this report underscores the complexity of Kir4.1 alterations in astrocytes and astrocytic tumor cells, and the potential contribution of the local inflammatory environment, involving in particular the pro-inflammatory cytokine IL-1β, in regulating the expression of Kir4.1 in epilepsy-associated lesions. Whether this mechanism could play a role in other neurological disorders (multiple sclerosis, neurodegenerative disorders) characterized by high levels of IL-1β and dysfunction of Kir4.1 [49,66,67] deserves further investigation.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
The experiments in the rat model of temporal lobe epilepsy were performed by JG and EvV. Cell culture experiments were performed by EZ and AI. Immunohistochemistry, qPCR, western blot, and analysis of the data were performed by EZ, MG, AI, and JA. EZ, MG, JG, and AI helped EA in drafting and preparing the manuscript for submission. The overall experimental design was conceived and supervised by EA, JG, JR, and JH. MG, JR, and JH helped in the selection and collection of brain tissues. We are grateful to Caterina Carbonell for technical assistance. All authors read and approved the final manuscript.
This work has been supported by National Epilepsy Funds, NEF 09–05, EU FP7 project NeuroGlia, Grant Agreement N° 202167 (AE); NEF07-19 (JAG); and an unrestricted grant of UCB Pharma (MG).
Aronica E, Ravizza T, Zurolo E, Vezzani A: Astrocyte immune responses in epilepsy.
Glia 2012, 60:1258-1268. PubMed Abstract | Publisher Full Text
Steinhauser C, Seifert G: Astrocyte dysfunction in epilepsy. In Jasper's Basic Mechanisms of the Epilepsies [Internet]. 4th edition. Edited by Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV. Bethesda (MD): National Center for Biotechnology Information (US); 2012. PubMed Abstract | Publisher Full Text
Steinhauser C, Seifert G: Glial membrane channels and receptors in epilepsy: impact for generation and spread of seizure activity.
Eur J Pharmacol 2002, 447:227-237. PubMed Abstract | Publisher Full Text
Seifert G, Carmignoto G, Steinhauser C: Astrocyte dysfunction in epilepsy.
Brain Res Rev 2010, 63:212-221. PubMed Abstract | Publisher Full Text
Djukic B, Casper KB, Philpot BD, Chin LS, McCarthy KD: Conditional knock-out of Kir4.1 leads to glial membrane depolarization, inhibition of potassium and glutamate uptake, and enhanced short-term synaptic potentiation.
J Neurosci 2007, 27:11354-11365. PubMed Abstract | Publisher Full Text
Chever O, Djukic B, McCarthy KD, Amzica F: Implication of Kir4.1 channel in excess potassium clearance: an in vivo study on anesthetized glial-conditional Kir4.1 knock-out mice.
J Neurosci 2010, 30:15769-15777. PubMed Abstract | Publisher Full Text
Bockenhauer D, Feather S, Stanescu HC, Bandulik S, Zdebik AA, Reichold M, Tobin J, Lieberer E, Sterner C, Landoure G, Arora R, Sirimanna T, Thompson D, Cross JH, van't Hoff W, Al Masri O, Tullus K, Yeung S, Anikster Y, Klootwijk E, Hubank M, Dillon MJ, Heitzmann D, Arcos-Burgos M, Knepper MA, Dobbie A, Gahl WA, Warth R, Sheridan E, Kleta R: Epilepsy, ataxia, sensorineural deafness, tubulopathy, and KCNJ10 mutations.
N Eng J Med 2009, 360:1960-1970. Publisher Full Text
Haj-Yasein NN, Jensen V, Vindedal GF, Gundersen GA, Klungland A, Ottersen OP, Hvalby O, Nagelhus EA: Evidence that compromised K + spatial buffering contributes to the epileptogenic effect of mutations in the human Kir4.1 gene (KCNJ10).
Glia 2011, 59:1635-1642. PubMed Abstract | Publisher Full Text
Olsen ML, Sontheimer H: Functional implications for Kir4.1 channels in glial biology: from K + buffering to cell differentiation.
J Neurochem 2008, 107:589-601. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Schroder W, Hinterkeuser S, Seifert G, Schramm J, Jabs R, Wilkin GP, Steinhauser C: Functional and molecular properties of human astrocytes in acute hippocampal slices obtained from patients with temporal lobe epilepsy.
Jauch R, Windmuller O, Lehmann TN, Heinemann U, Gabriel S: Effects of barium, furosemide, ouabaine and 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid (DIDS) on ionophoretically-induced changes in extracellular potassium concentration in hippocampal slices from rats and from patients with epilepsy.
Brain Res 2002, 925:18-27. PubMed Abstract | Publisher Full Text
Heinemann U, Gabriel S, Jauch R, Schulze K, Kivi A, Eilers A, Kovacs R, Lehmann TN: Alterations of glial cell function in temporal lobe epilepsy.
Kivi A, Lehmann TN, Kovacs R, Eilers A, Jauch R, Meencke HJ, von Deimling A, Heinemann U, Gabriel S: Effects of barium on stimulus-induced rises of [K+]o in human epileptic non-sclerotic and sclerotic hippocampal area CA1.
Eur J Neurosci 2000, 12:2039-2048. PubMed Abstract | Publisher Full Text
Bordey A, Sontheimer H: Electrophysiological properties of human astrocytic tumor cells In situ: enigma of spiking glial cells.
J Neurophysiol 1998, 79:2782-2793. PubMed Abstract | Publisher Full Text
Stewart TH, Eastman CL, Groblewski PA, Fender JS, Verley DR, Cook DG, D'Ambrosio R: Chronic dysfunction of astrocytic inwardly rectifying K + channels specific to the neocortical epileptic focus after fluid percussion injury in the rat.
J Neurophysiol 2010, 104:3345-3360. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Warth A, Mittelbronn M, Wolburg H: Redistribution of the water channel protein aquaporin-4 and the K + channel protein Kir4.1 differs in low- and high-grade human brain tumors.
Acta Neuropathol 2005, 109:418-426. PubMed Abstract | Publisher Full Text
Tan G, Sun SQ, Yuan DL: Expression of Kir 4.1 in human astrocytic tumors: correlation with pathologic grade.
Biochem Biophys Res Commun 2008, 367:743-747. PubMed Abstract | Publisher Full Text
Olsen ML, Sontheimer H: Mislocalization of Kir channels in malignant glia.
Glia 2004, 46:63-73. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Ivens S, Kaufer D, Flores LP, Bechmann I, Zumsteg D, Tomkins O, Seiffert E, Heinemann U, Friedman A: TGF-beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis.
Brain 2007, 130:535-547. PubMed Abstract | Publisher Full Text
Olsen ML, Campbell SC, McFerrin MB, Floyd CL, Sontheimer H: Spinal cord injury causes a wide-spread, persistent loss of Kir4.1 and glutamate transporter 1: benefit of 17 beta-oestradiol treatment.
Brain 2010, 133:1013-1025. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Zhang Y, Xu G, Ling Q, Da C: Expression of aquaporin 4 and Kir4.1 in diabetic rat retina: treatment with minocycline.
J Int Med Res 2011, 39:464-479. PubMed Abstract | Publisher Full Text
Vezzani A, Maroso M, Balosso S, Sanchez MA, Bartfai T: IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures.
Brain Behav Immun 2011, 25:1281-1289. PubMed Abstract | Publisher Full Text
Aronica E, Crino PB: Inflammation in epilepsy: clinical observations.
Kim JE, Choi HC, Song HK, Jo SM, Kim DS, Choi SY, Kim YI, Kang TC: Levetiracetam inhibits interleukin-1 beta inflammatory responses in the hippocampus and piriform cortex of epileptic rats.
Neurosci Lett 2010, 471:94-99. PubMed Abstract | Publisher Full Text
Stienen MN, Haghikia A, Dambach H, Thone J, Wiemann M, Gold R, Chan A, Dermietzel R, Faustmann PM, Hinkerohe D, Prochnow N: Anti-inflammatory effects of the anticonvulsant drug levetiracetam on electrophysiological properties of astroglia are mediated via TGFbeta1 regulation.
Gorter JA, van Vliet EA, Aronica E, da Silva FHL: Progression of spontaneous seizures after status epilepticus is related with extensive bilateral loss of hilar parvalbumin and somatostatin immunoreactive neurons.
Eur J Neurosci 2001, 13:657-669. PubMed Abstract | Publisher Full Text
Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC: Measurement of protein using bicinchoninic acid [published erratum appears in Anal Biochem 1987 May 15;163(1):279].
Anal Biochem 1985, 150:76-85. PubMed Abstract | Publisher Full Text
Aronica E, Gorter JA, Ijlst-Keizers H, Rozemuller AJ, Yankaya B, Leenstra S, Troost D: Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins.
Eur J Neurosci 2003, 17:2106-2118. PubMed Abstract | Publisher Full Text
Aronica E, Gorter JA, Rozemuller AJ, Yankaya B, Troost D: Interleukin-1 beta down-regulates the expression of metabotropic glutamate receptor 5 in cultured human astrocytes.
J Neuroimmunol 2005, 160:188-194. PubMed Abstract | Publisher Full Text
Aronica E, Gorter JA, Redeker S, van Vliet EA, Ramkema M, Scheffer GL, Scheper RJ, van der Valk P, Leenstra S, Baayen JC, Spliet WG, Troost D: Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain.
Epilepsia 2005, 46:849-857. PubMed Abstract | Publisher Full Text
Ramakers C, Ruijter JM, Deprez RH, Moorman AF: Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data.
Neurosci Lett 2003, 339:62-66. PubMed Abstract | Publisher Full Text
Louis DN, Ohgaki H, Wiestler OD, Cavanee WK: WHO Classification of Tumours of the Central Nervous System. Lyon: IARC; 2007.
Ravizza T, Boer K, Redeker S, Spliet WGM, van Rijen PC, Troost D, Vezzani A, Aronica E: The IL-1 system in epilepsy-associated malformations of cortical development.
Neurobiol Dis 2006, 24:128-143. PubMed Abstract | Publisher Full Text
Maroso M, Balosso S, Ravizza T, Liu J, Aronica E, Iyer AM, Rossetti C, Molteni M, Manfredi AA, Bianchi ME, Vezzani A: Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures.
Nat Med 2010, 16:413-419. PubMed Abstract | Publisher Full Text
de Groot M, Reijneveld JC, Aronica E, Heimans JJ: Epilepsy in patients with a brain tumour: focal epilepsy requires focused treatment.
Brain 2012, 135:1002-1016. PubMed Abstract | Publisher Full Text
Aronica E, Gorter JA, Redeker S, Ramkema M, Spliet WG, van Rijen PC, Leenstra S, Troost D: Distribution, characterization and clinical significance of microglia in glioneuronal tumours from patients with chronic intractable epilepsy.
Neuropathol Appl Neurobiol 2005, 31:280-291. PubMed Abstract | Publisher Full Text
de Groot M, Iyer A, Zurolo E, Anink J, Heimans JJ, Boison D, Reijneveld JC, Aronica E: Overexpression of ADK in human astrocytic tumors and peritumoral tissue is related to tumor-associated epilepsy.
Epilepsia 2012, 53:58-66. PubMed Abstract | Publisher Full Text
Dinarello CA: Biologic basis for interleukin-1 in disease.
Blood 1996, 87:2095-2147. PubMed Abstract | Publisher Full Text
Andersson A, Covacu R, Sunnemark D, Danilov AI, Dal Bianco A, Khademi M, Wallstrom E, Lobell A, Brundin L, Lassmann H, Harris RA: Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis.
J Leukoc Biol 2008, 84:1248-1255. PubMed Abstract | Publisher Full Text
Hreggvidsdottir HS, Ostberg T, Wahamaa H, Schierbeck H, Aveberger AC, Klevenvall L, Palmblad K, Ottosson L, Andersson U, Harris HE: The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation.
J Leukoc Biol 2009, 86:655-662. PubMed Abstract | Publisher Full Text
Bianchi ME: HMGB1 loves company.
J Leukoc Biol 2009, 86:573-576. PubMed Abstract | Publisher Full Text
Gorter JA, Van Vliet E, Aronica E, Rauwerda H, Breit T, Lopes da Silva FH, Wadman WJ: Potential new antiepileptogenic targets indicated by microarray analysis in a rat model for temporal lobe epilepsy.
J Neurosci 2006, 26:11083-11110. PubMed Abstract | Publisher Full Text
De Simoni MG, Perego C, Ravizza T, Moneta D, Conti M, Marchesi F, De Luigi A, Garattini S, Vezzani A: Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus.
Eur J Neurosci 2000, 12:2623-2633. PubMed Abstract | Publisher Full Text
Patel HC, Boutin H, Allan SM: Interleukin-1 in the brain: mechanisms of action in acute neurodegeneration.
Ann N Y Acad Sci 2003, 992:39-47. PubMed Abstract | Publisher Full Text
Rothwell N: Interleukin-1 and neuronal injury: mechanisms, modification, and therapeutic potential.
Brain Behav Immun 2003, 17:152-157. PubMed Abstract | Publisher Full Text
Gibson RM, Rothwell NJ, Le Feuvre RA: CNS injury: the role of the cytokine IL-1.
Vet J 2004, 168:230-237. PubMed Abstract | Publisher Full Text
Pannicke T, Uckermann O, Iandiev I, Wiedemann P, Reichenbach A, Bringmann A: Ocular inflammation alters swelling and membrane characteristics of rat Muller glial cells.
J Neuroimmunol 2005, 161:145-154. PubMed Abstract | Publisher Full Text
Reichenbach A, Wurm A, Pannicke T, Iandiev I, Wiedemann P, Bringmann A: Muller cells as players in retinal degeneration and edema.
Graefes Arch Clin Exp Ophthalmol 2007, 245:627-636. PubMed Abstract | Publisher Full Text
Kaiser M, Maletzki I, Hulsmann S, Holtmann B, Schulz-Schaeffer W, Kirchhoff F, Bahr M, Neusch C: Progressive loss of a glial potassium channel (KCNJ10) in the spinal cord of the SOD1 (G93A) transgenic mouse model of amyotrophic lateral sclerosis.
J Neurochem 2006, 99:900-912. PubMed Abstract | Publisher Full Text
Lucas SM, Rothwell NJ, Gibson RM: The role of inflammation in CNS injury and disease.
Zhang Z, Zhang ZY, Fauser U, Schluesener HJ: Valproic acid attenuates inflammation in experimental autoimmune neuritis.
Cell Mol Life Sci. 2008, 65:4055-4065. PubMed Abstract | Publisher Full Text
Giometto B, Bozza F, Faresin F, Alessio L, Mingrino S, Tavolato B: Immune infiltrates and cytokines in gliomas.
Acta Neuroch 1996, 138:50-56. Publisher Full Text
Ishii N, Tada M, Sakuma S, Sawamura Y, Shinohe Y, Abe H: Human astrocytoma cells are capable of producing macrophage inflammatory protein-1beta.
J Neurooncol 1998, 37:17-23. PubMed Abstract | Publisher Full Text
Sasaki A, Tamura M, Hasegawa M, Ishiuchi S, Hirato J, Nakazato Y: Expression of interleukin-1beta mRNA and protein in human gliomas assessed by RT-PCR and immunohistochemistry.
J Neuropathol Exp Neurol 1998, 57:653-663. PubMed Abstract | Publisher Full Text
Sharma V, Dixit D, Koul N, Mehta VS, Sen E: Ras regulates interleukin-1beta-induced HIF-1alpha transcriptional activity in glioblastoma.
J Mol Med 2011, 89:123-136. PubMed Abstract | Publisher Full Text
Iwami K, Natsume A, Wakabayashi T: Cytokine networks in glioma.
Neurosurg Rev 2011, 34:253-263.
discussion 263–254.PubMed Abstract | Publisher Full Text
Vezzani A, Ravizza T, Balosso S, Aronica E: Glia as a source of cytokines: implications for neuronal excitability and survival.
Epilepsia 2008, 49:24-32. PubMed Abstract | Publisher Full Text
Ye ZC, Sontheimer H: Glioma cells release excitotoxic concentrations of glutamate.
Cancer Res 1999, 59:4383-4391. PubMed Abstract | Publisher Full Text
Hu S, Sheng WS, Ehrlich LC, Peterson PK, Chao CC: Cytokine effects on glutamate uptake by human astrocytes.
Neuroimmunomodulation 2000, 7:153-159. PubMed Abstract | Publisher Full Text
Casamenti F, Prosperi C, Scali C, Giovannelli L, Colivicchi MA, Faussone-Pellegrini MS, Pepeu G: Interleukin-1beta activates forebrain glial cells and increases nitric oxide production and cortical glutamate and GABA release in vivo: implications for Alzheimer's disease.
Neuroscience 1999, 91:831-842. PubMed Abstract | Publisher Full Text
Vezzani A, Aronica E, Mazarati A, Pittman QJ: Epilepsy and brain inflammation.
Exp Neurol 2011.
[Epub ahead of print].
Hayakawa K, Arai K, Lo EH: Role of ERK map kinase and CRM1 in IL-1beta-stimulated release of HMGB1 from cortical astrocytes.
Glia 2010, 58:1007-1015. PubMed Abstract | Publisher Full Text
Zurolo E, Iyer A, Maroso M, Carbonell C, Anink JJ, Ravizza T, Fluiter K, Spliet WG, van Rijen PC, Vezzani A, Aronica E: Activation of Toll-like receptor, RAGE and HMGB1 signalling in malformations of cortical development.
Brain 2011, 134:1015-1032. PubMed Abstract | Publisher Full Text
Bassi R, Giussani P, Anelli V, Colleoni T, Pedrazzi M, Patrone M, Viani P, Sparatore B, Melloni E, Riboni L: HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration.
J Neurooncol 2008, 87:23-33. PubMed Abstract | Publisher Full Text
Thom M, Blumcke I, Aronica E: Long-term epilepsy-associated tumors.
Brain Pathol 2012, 22:350-379. PubMed Abstract | Publisher Full Text
Wilcock DM, Vitek MP, Colton CA: Vascular amyloid alters astrocytic water and potassium channels in mouse models and humans with Alzheimer's disease.
Neuroscience 2009, 159:1055-1069. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Srivastava R, Aslam M, Kalluri SR, Schirmer L, Buck D, Tackenberg B, Rothhammer V, Chan A, Gold R, Berthele A, Bennett JL, Korn T, Hemmer B: Potassium channel KIR4.1 as an immune target in multiple sclerosis.
N Engl J Med 2012, 367:115-123. PubMed Abstract | Publisher Full Text


text:
HOPKINTON — In a town-wide full revaluation, Hopkinton's property values were reduced by an average of 10.5 percent. Letters with updated property values were mailed to all town residents on April 9.
Rhode Island law mandates property valuation updates every three years to determine the fair market value of all real estate. Full revaluations are required every nine years and include inspection and remeasuring the interior and exterior of properties. Statistical valuations are performed every three years.
For the rest of this story and more local news, pick up a copy of the Chariho Times.
[1] http://www.ricentral.com/sites/default/files/SRI Logo_567.jpg


text:
It's simple:
- Get Reader Real Deal delivered daily to your email, Facebook or Twitter accounts. Each deal will provide exclusive discounts starting at 50% off retail prices at local restaurants, salons, events and more.
- Each deal is only valid for a limited time, so you'll have to act fast in order to take advantage of the savings. Just follow the "Buy Now!" link from our homepage.
- Don't forget to extend the savings to your friends and family! It's more fun to share the experience with others, and you'll get your deal for free if three of your friends purchase the same deal with your referral link!
- Once you've made a purchase, print your certificate from your account and present it to the merchant to reap your savings.
- Log into your account anytime to view your purchases, reprint your certificates, assign certificates as gifts or update your billing information.
That's all there is to it. Sign up today and start saving!


text:
Refurbished 24-inch ViewSonic HD LCD Display, cut to $167
Macmall.com's Deal of the Day today is the refurbished ViewSonic 24-inch 1080P HD LCD Widescreen Display (model no. VX2433WM-S) priced at $167.99, which delivers a maximum screen resolution of 1920 x
Onsale.com also has a refurbished display as is Steal of the Day, the Vizio 42-inch LCD HDTV with built-in ATSC/QAM Tuner. This HDTV offers many of the same specs found in the ViewSonic, and has dropped $180 in price. Its final cost sits at $569.99 and has shipping rates starting at $35.56. Tigerdirect.com this week is offering two larger and popular solutions, the first being the Toshiba Regza 47-inch LCD HDTV with ClearScan, while the second is the 52-inch Toshiba Regza LCD HDTV. The 47-inch is currently on sale for $899.99 and offers savings of $800, while the 52-inch has dropped $650 and is now priced at $1,149.99 with shipping rates starting at $49.


text:
webcam chat sexyOct 9, 2008
... - Are you looking for a free webcam chat where you can chat to users and get naughty on your cam well try ...Adult webcams - Live webcam video chat with sexy girls, boys, groups, coupls, gays. More than 800 webcams online now!LIVE SEX WEB CAM VIDEO CHAT LIVE SEX SHOWS DivasCam the nets ... live cam community featuring sexy amateurs and live girls from all over the world.
...Voici plus de 100 filles a admirer, des modeles venues du monde entier connectees a votre webcam sexy, pour vous offrir des shows de free sex.Webcam Free Shows with Hundreds of Live Sexy Hot Babes. ... It is free webcam to video chat with these webcam free beauties but if you want more than that, ...A webcam chat for teenagers between 14 and 19
. No need for registration. No adults allowed. Only for teenagers. Start your cam and chat with boys and girls ...Chat free with sexy naked girls from around the world who love to show all on two way webcam.Cam2sex is a free adult webcam website that features hot and sexy cam girls who are ready to chat with you. Come join us and chat with sexy cam girls live.yet another very sexy fuckable webcam teen from the LiveJasmin crew! .
.. just waiting for a chance for someone like you to visit their free webcam chat page, [...] ...Top Chat Sites. Meet teen and adult people and find free chats. ...


text:
Flipkart is selling Campus Running Shoes Starting at Rs.499 only along with free shipping . So purchase these shoe at low prices that to from most popular e-commerce site flipkart.com
How to get Campus Running Shoes at Rs. 499 from Flipkart:
- Visit here for campus Shoes offer page on Flipkart
- Select any shoe of your choice and size
- Add it to the cart
- Login/Register
- Fill/Update shipping details
- Make payment


text:
An area special olympian received a big honor last night.
Billy Noss, the area's oldest competing special olympic athlete, had two surprises last night. One was a 75th birthday party at Carson Park. The other was being named an honorary officer with the Eau Claire Police Department, complete with a real badge. Besides playing softball with Special Olympics, Noss has been a volunteer for several groups, who showed up to honor him last night. In a couple of days, he'll head to Onalaska to play in a softball competition.
Simply confirm your registered email address below and click "Reset Password." We will immediately email you a link back to the site where you can enter a new password for this account.


text:
Welcome to the Crazy Cupid Love Valentine's Giveaway Event hosted by Sweep Tight and Just Married with Coupons featuring over 80 SUPER EASY-to-enter giveaways valued at $10 or more! After you enter to win our giveaway, make sure to hop over to all of the other participating blogs to enter to win lots of prizes! See the participating links at the bottom of this post!
Our sponsor is ShopBop! They are offering a $100 Gift Certificate to two lucky winners!
ShopBop is an online shopping website that has a huge variety of name brands at a bargain. It is a great resource for fashionable items like: Marc by Marc Jacobs bikinis, Shoshanna, Juicy Couture swimwear and much more!
Make sure to Fan Shopbop on Facebook, too!
PRIZE: 2 lucky winners will receive a $100 ShopBop Gift Certificate
-Giveaway is open Worldwide, 18+
-Giveaway ends on 2/7/2012 at midnight EST
-Entries are only valid through the Rafflecopter Form
-Comments do not count as entries
a Rafflecopter giveaway


text:
- 97Promote
Art Print
beardby Iris Lehnhardt
Collect your choice of gallery quality Giclée, or fine art prints custom trimmed by hand in a variety of sizes with a white border for framing.
This piece is quite beautiful.
oh wie schön, so ein tolles, sattes grün.. ♥
Very lovely!
Really pretty colors and capture!
pure zen.
so beautiful!
Very happy about your great comments! Thank you!! ♥
Beatiful Iris!!! :D
Perfection, Iris style!!
Soft and beautiful!!
Carina, Angela, Angelo, Yasmina and ADIDA: thank you so very much for your kind comments, I´m delighted :-)
. ╰⊰✿ . . beautiful concept . . ✿⊱╮.
This way it is an awesome abstract
See More Comments


text:
Wednesday February 13, 2013No. 3 Florida Lacrosse Tops Jacksonville 15-4
Jacksonville, Fla.
Jacksonville, Fla.
Senior attack Gabi Wiegand (Bay Shore, N.Y.) scored five goals as she helped lead No. 3 Florida to a 15-4 win over Jacksonville on Wednesday night at Southern Oaks Stadium.
Eight different Gators scored on the evening and held the Dolphins (1-2) to just one goal in the second half en route to their second victory of the season. Senior attack Kitty Cullen (Rockville, Md.), senior midfielder Brittany Dashiell (Bel Air, Md.) and sophomore midfielder Shannon Gilroy (Northport, N.Y.) each added two goals in the win. Six different Gators also added assists in the contest.
I thought they did a fantastic job, I thought Gabi (Wiegand) did a great job driving to the goal and Brittany (Dashiell) drawing too and being able to distribute the ball. We got a lot of opportunities, a lot of shots and thats what we were looking for tonight, Head coach Amanda OLeary said.
Florida (2-0) controlled the tempo on both sides of the field, leading the game in shots (31-13), ground balls (19-8), draw controls (13-8) and forced 10 turnovers in the contest.
Gilroy, Barry and senior defender Kayla Stolins (Glen Arm, Md.) led with three draw controls each while Dashiell added two. Senior attack Caroline Chesterman (South Nyack, N.Y.) led with four ground balls while Wiegand, senior defender Emily Dohony and freshman midfielder Sydney DuPre picked up two each.
Jacksonville controlled the opening draw and used nearly three minutes of the clock as they scored first. Cullen answered by scoring back-to-back goals to regain the lead with just under eight minutes in the game. Dashiell added another goal in the next minute to bump the Gators lead 3-1.
Wiegand made it a 4-1 game on a free position shot as the Dolphins Amanda Hurley answered with a goal. Thats when the Florida defense kicked in, holding Jacksonville scoreless for the next 12 minutes. OLeary credit defensive play by ALC Players of the Week senior goalie Mikey Meagher (Liverpool, N.Y.) and freshman midfielder Sydney DuPre (Houston, Texas) among others on stopping Jacksonvilles offensive attack.
I thought Emily Dohony did a great job tonight OLeary said They (Jacksonville) like to drive the crease and I thought Jamie (Reeg) and Emily did a great job of denying that, Sam did a great job on the wing and Sydney had another fantastic night.
Meagher had six saves on the night, including four in the second half on a total of 13 shots by the Dolphins.
Ultimately, I feel that whole defensive unit did a fantastic job, OLeary said.
Freshman attack Lauren Lea (Elkridge, Md.) scored the first goal of her Gator career off an assist by Dashiell with 10:04 left to play in the first half. Senior attack Ashley Bruns (Ellicot City, Md.) chipped in a goal off an assist by Chesterman while sophomore midfielder Nora Barry (Marcellus, N.Y.) found the goal for the first time this season while Wiegand helped make the score 8-2 headed into the final two minutes before the half.
Jacksonvilles Hurley scored her second goal of the game with but Wiegand found the back of the net again with :14 seconds remaining helping the Gators to a 9-3 halftime lead. The Gators defense held JU to only five shots in the first half and forced seven turnovers before the break.
It was all Florida in the second half as JU could only muster one goal after the break on a Hurley goal seven minutes into the half. Wiegand and Gilroy added two goals while Dashiell scored oneb for UF in the second half while freshman midfielder Devon Schneider (Lilitz, Pa.) scored her first career goal with just under two minutes to play in the game off an assist by freshman midfielder Carly Ross (Freeland, Md.).
The Gators are back in action on Sunday as they travel to High Point, N.C. to face High Point. Opening draw is set for 1 p.m.
For all of the latest information on Florida lacrosse, please log on to www.GatorZone.com/lacrosse or, for up-to-the-minute updates, follow Florida lacrosse on Twitter at @GatorZoneLAX or www.twitter.com/GatorZoneLAX. You can also find the Gators on Facebook.
© 1998 - 2015 University Athletic Assoc., Inc., FOX Sports Sun & IMG College. All Rights Reserved.